Diabetes Care, Vol 21, Issue 10 1720-1725, Copyright © 1998 by American Diabetes Association

ARTICLES

The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus

JL Chiasson, R Gomis, M Hanefeld, RG Josse, A Karasik and M Laakso
Centre Hospitalier de L'Universite de Montreal, Department of Medicine, University of Montreal, Quebec, Canada. chiassoj@ere.umontreal.ca

OBJECTIVE: To describe the rationale and design, and to discuss the preliminary screening data, of the Study to Prevent NIDDM (STOP-NIDDM Trial), an international study on the efficacy of the alpha-glucosidase inhibitor acarbose in preventing or delaying the development of type 2 diabetes in a population with impaired glucose tolerance (IGT). RESEARCH DESIGN AND METHODS: A total of 1,418 subjects diagnosed with IGT according to the World Health Organization's criteria and having a fasting plasma glucose concentration > or =5.6 mmol/L were randomized in a double-blind fashion to receive either acarbose (100 mg t.i.d.) or placebo for a predictive median follow-up period of 3.9 years. The primary outcome is the development of type 2 diabetes diagnosed using a 75-g oral glucose tolerance test according to the new criteria. The secondary outcomes are changes in blood pressure, lipid profile, insulin sensitivity, cardiovascular events, and morphometric profile. RESULTS: Screening was performed in a high-risk population. As of 1 March 1997, 4,424 subjects had been screened, and data were available for 3,919 (88.5%) subjects. Of these subjects, 1,200 (30.6%) had glucose intolerance. Of the subjects with glucose intolerance, 521 (13.3%) had previously undetected type 2 diabetes, and 679 (17.3%) had IGT. Of the IGT population, 412 (60.7%) subjects were eligible for the study This population had the following characteristics: the mean age was 54.8 years, 52% of the subjects were female, 53% had more than one risk factor for type 2 diabetes, >90% had a family history of diabetes, 78.2% had a BMI > or =27 kg/m2, 47.5% had high blood pressure, 51.2% had dyslipidemia, and 22.8% of the women had a history of gestational diabetes. CONCLUSIONS: Screening of a high-risk population yields one eligible subject per every 10 volunteers screened. This study should definitely answer the question of whether acarbose can prevent or delay the progression of IGT to type 2 diabetes mellitus.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. L. Norris, D. Kansagara, C. Bougatsos, and R. Fu Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, June 3, 2008; 148(11): 855 - 868. [Abstract] [Full Text] [PDF]

				M. Mudra, N. Ercan-Fang, L. Zhong, J. Furne, and M. Levitt Influence of Mulberry Leaf Extract on the Blood Glucose and Breath Hydrogen Response to Ingestion of 75 g Sucrose by Type 2 Diabetic and Control Subjects Diabetes Care, May 1, 2007; 30(5): 1272 - 1274. [Full Text] [PDF]

				L. Andrulionyte, P. Peltola, J.-L. Chiasson, M. Laakso, and for the STOP-NIDDM Study Group Single Nucleotide Polymorphisms of PPARD in Combination With the Gly482Ser Substitution of PGC-1A and the Pro12Ala Substitution of PPARG2 Predict the Conversion From Impaired Glucose Tolerance to Type 2 Diabetes: The STOP-NIDDM Trial. Diabetes, July 1, 2006; 55(7): 2148 - 2152. [Abstract] [Full Text] [PDF]

				J. Zacharova, J.-L. Chiasson, M. Laakso, and the STOP-NIDDM Study Group The Common Polymorphisms (Single Nucleotide Polymorphism [SNP] +45 and SNP +276) of the Adiponectin Gene Predict the Conversion From Impaired Glucose Tolerance to Type 2 Diabetes: The STOP-NIDDM Trial Diabetes, March 1, 2005; 54(3): 893 - 899. [Abstract] [Full Text] [PDF]

				D. C Anderson Jr Pharmacologic Prevention or Delay of Type 2 Diabetes Mellitus Ann. Pharmacother., January 1, 2005; 39(1): 102 - 109. [Abstract] [Full Text] [PDF]

				R. S. Legro, E. Myers, and for the Reproductive Medicine Network Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome? Hum. Reprod., August 1, 2004; 19(8): 1697 - 1704. [Abstract] [Full Text] [PDF]

				M. Hanefeld, J. L. Chiasson, C. Koehler, E. Henkel, F. Schaper, and T. Temelkova-Kurktschiev Acarbose Slows Progression of Intima-Media Thickness of the Carotid Arteries in Subjects With Impaired Glucose Tolerance Stroke, May 1, 2004; 35(5): 1073 - 1078. [Abstract] [Full Text] [PDF]

				L. M. Prisant Preventing Type II Diabetes Mellitus J. Clin. Pharmacol., April 1, 2004; 44(4): 406 - 413. [Abstract] [Full Text] [PDF]

				M. J. Abrahamson Optimal Glycemic Control in Type 2 Diabetes Mellitus: Fasting and Postprandial Glucose in Context Arch Intern Med, March 8, 2004; 164(5): 486 - 491. [Abstract] [Full Text] [PDF]

				J. S Torgerson Review: Preventing diabetes in the obese: the XENDOS study and its context The British Journal of Diabetes & Vascular Disease, January 1, 2004; 4(1): 22 - 27. [Abstract] [PDF]

				Prevention or Delay of Type 2 Diabetes Diabetes Care, January 1, 2004; 27(90001): s47 - 47. [Full Text] [PDF]

				T. Kaiser and P. T. Sawicki Acarbose for Patients With Hypertension and Impaired Glucose Tolerance JAMA, December 17, 2003; 290(23): 3066 - 3066. [Full Text] [PDF]

				J.-L. Chiasson, R. G. Josse, R. Gomis, M. Hanefeld, A. Karasik, and M. Laakso Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance: The STOP-NIDDM Trial JAMA, July 23, 2003; 290(4): 486 - 494. [Abstract] [Full Text] [PDF]

				The Prevention or Delay of Type 2 Diabetes Diabetes Care, January 1, 2003; 26(90001): s62 - 69. [Full Text] [PDF]

				The Prevention or Delay of Type 2 Diabetes Clin. Diabetes, July 1, 2002; 20(3): 109 - 116. [Full Text] [PDF]

				The Prevention or Delay of Type 2 Diabetes Diabetes Spectr, July 1, 2002; 15(3): 147 - 157. [Full Text] [PDF]

				American Diabetes Association The Prevention or Delay of Type 2 Diabetes Diabetes Care, April 1, 2002; 25(4): 742 - 749. [Full Text] [PDF]

				J. K. Bardsley and M. Passaro ABCs of Diabetes Research Clin. Diabetes, January 1, 2002; 20(1): 5 - 8. [Abstract] [Full Text] [PDF]

				S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring Pathophysiology and Pharmacological Treatment of Insulin Resistance Endocr. Rev., December 1, 2000; 21(6): 585 - 618. [Abstract] [Full Text]

				S. M. Haffner, L. Mykkanen, A. Festa, J. P. Burke, and M. P. Stern Insulin-Resistant Prediabetic Subjects Have More Atherogenic Risk Factors Than Insulin-Sensitive Prediabetic Subjects : Implications for Preventing Coronary Heart Disease During the Prediabetic State Circulation, March 7, 2000; 101(9): 975 - 980. [Abstract] [Full Text] [PDF]